Drugs / MAGE-3.1
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00003792 | Apr 1999 → Oct 2006 | cutaneous melanoma | Baylor Health Care System | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01307618 | Feb 2011 → Jan 2015 | melanoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 2 | NCT00085189 | May 2004 → Sep 2007 | iris melanoma, medium/large size posterior uveal melanoma, mucosal melanoma, ocular melanoma with extraocular extension +1 | University of Southern California | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MAGE-3.1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00085189 ↗ |
| Modality | Protein / enzyme biologic | “recombinant MAGE-3.1 antigen” NCT00003792 ↗ |
| Route | Subcutaneous | “Given SC or ID” NCT01307618 ↗ |